These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 24582540)

  • 21. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Primary and secondary prevention of benign prostatic hyperplasia: current knowledge and implications for clinical management].
    Oelke M; Madersbacher S
    Urologe A; 2011 Oct; 50(10):1257-8, 1260-4. PubMed ID: 21901570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
    Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
    Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.
    Mullins C; Lucia MS; Hayward SW; Lee JY; Levitt JM; Lin VK; Liu BC; Chinnaiyan AM; Rubin MA; Slawin K; Star RA; Getzenberg RH;
    J Urol; 2008 Apr; 179(4):1243-56. PubMed ID: 18280515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation and medical management of benign prostatic hyperplasia.
    Beckman TJ; Mynderse LA
    Mayo Clin Proc; 2005 Oct; 80(10):1356-62. PubMed ID: 16212149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Latest trends and recommendations on epidemiology, diagnosis, and treatment of benign prostatic hyperplasia (BPH)].
    Gabuev A; Oelke M
    Aktuelle Urol; 2011 May; 42(3):167-78. PubMed ID: 21604233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
    Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N
    J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Finasteride in the treatment of benign prostatic hyperplasia].
    Ząbkowski T
    Urologe A; 2012 Jul; 51(7):982-6. PubMed ID: 22772497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial.
    Kaplan SA; Lee JY; Meehan AG; Kusek JW;
    J Urol; 2011 Apr; 185(4):1369-73. PubMed ID: 21334655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis.
    Nickel JC
    Curr Opin Urol; 2006 Jan; 16(1):5-10. PubMed ID: 16385194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary.
    Spatafora S; Conti G; Perachino M; Casarico A; Mazzi G; Pappagallo GL;
    Curr Med Res Opin; 2007 Jul; 23(7):1715-32. PubMed ID: 17588302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
    Smith AB; Carson CC
    Ther Clin Risk Manag; 2009 Jun; 5(3):535-45. PubMed ID: 19707263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
    Helfand BT; Blackwell RH; McVary KT
    J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
    O'Leary MP
    Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.